Content Status
Type
Linked Node
DR-TB Treatment Care Cascade
Learning ObjectivesDR-TB Treatment Care Cascade
The Drug-resistant TB (DR-TB) treatment process for all DR-TB patients follows a care cascade.
- DR-TB patient tracing by health staff
- Referral for treatment initiation to health facility/ district or nodal DR-TB site
- Pre-treatment evaluation
- Decision on patient’s treatment regimen by DR-TB committee
- DR-TB treatment initiation*
- Counselling of patient and his/her family
- Treatment supporter identification in consultation with the patient
- Active Drug Safety Monitoring (aDSM) form filling
- Adverse Drug Reaction (ADR) Management (as and when needed)
- Follow up visits to the nearest Health Facility (HF)
- Adverse Drug Reaction (ADR) Management (as and when needed)
- Active Drug Safety Monitoring (aDSM) form filling
- Treatment supporter identification in consultation with the patient
- Counselling of patient and his/her family
- DR-TB treatment initiation*
- Referral for treatment initiation to health facility/ district or nodal DR-TB site
*(H Mono/ Poly DR-TB Patient - Any health facility; Multidrug/ Extensively DR-TB (M/ XDR-TB) Patient - Nodal/ District DR-TB Centre (N/DDR-TBC); Contact of MDR/ DD-TB with FQ-susceptibility - TB Preventive Therapy after ruling out active disease)
HFs are responsible for updating the information of DR-TB patients in Nikshay on a real-time basis.
This entire care cascade needs to be monitored by the Medical Officer of the TB Unit (MO-TU) and the senior DR-TB TB-HIV supervisor. The figure below elaborates on these processes that should be followed in the DR-TB treatment care cascade.
Figure: Processes for all DR-TB Patients in the Treatment Care Cascade; Source: PMDT Guidelines India, 2021, p43.
Abbr: PTE: Pre-treatment Evaluation; ADR: Adverse Drug Reaction; aDSM: Active Drug Safety Monitoring
Resources
- Guidelines for Programmatic Management of Drug-resistant Tuberculosis in India, March 2021.
- Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-resistant Tuberculosis, 2014.
- WHO Consolidated Guidelines on Tuberculosis, Module 4 - Treatment: Drug-resistant TB Treatment.
Kindly provide your valuable feedback on the page to the link provided HERE
Content Creator
Reviewer
Target Audience
- Log in to post comments